Finance

Lists
AVBP:NASDAQ
Arrivent Biopharma Inc
၂၉.၅၁ US$
-၁.၆၃%
(-၀.၄၉) 1D
၂၉.၅၁ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: ဩ ၁၄, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVBP...
Open
၂၉.၉၉ US$
High
၃၀.၀၇ US$
Low
၂၉.၁၃ US$
Mkt. cap
၁၄၅.၅၁ ဋေ
Avg. vol.
၄.၈၁ သိန်း
Volume
၄.၃၉ သိန်း
52-wk high
၃၅.၈၃ US$
52-wk low
၁၇.၀၀ US$
EPS
-၃.၆၇ US$
Shares outstanding
၄.၉၃ ကုဋေ
No. of employees
၇၇
Open
၂၉.၉၉ US$
High
၃၀.၀၇ US$
Low
၂၉.၁၃ US$
Mkt. cap
၁၄၅.၅၁ ဋေ
Avg. vol.
၄.၈၁ သိန်း
Volume
၄.၃၉ သိန်း
52-wk high
၃၅.၈၃ US$
52-wk low
၁၇.၀၀ US$
EPS
-၃.၆၇ US$
Shares outstanding
၄.၉၃ ကုဋေ
No. of employees
၇၇
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၂ နာရီ
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal
Stock Traders Daily
Stock Traders Daily
·
ပြီးခဲ့သည့် ၁ ရက်
Technical Reactions to AVBP Trends in Macro Strategies
About Arrivent Biopharma Inc
CEO-
Employees၇၇
Founded၂၀၂၁
HeadquartersNewtown Square, ပင်ဆယ်ဗေးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitearrivent.com
Analyst ratings
Based on 8 analysts giving stock ratings to AVBP in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for AVBP in the last 3 months.
Highest
Current ၂၉.၅၁ US$
၅၀.၀၀ US$ (+၆၉.၄၃%)
Average
၄၄.၃၈ US$ (+၅၀.၃၉%)
Lowest
၄၀.၀၀ US$ (+၃၅.၅၅%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
၄၀.၀၀ US$
+၃၅.၅%
08/14/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
၄၅.၀၀ US$
+၅၂.၅%
08/13/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
၄၅.၀၀ US$
+၅၂.၅%
08/13/2026
Jeff Jones
Oppenheimer
Buy
Maintained
၅၀.၀၀ US$
+၆၉.၄%
08/13/2026
Jeet Mukherjee
BTIG
Buy
Maintained
၄၂.၀၀ US$
+၄၂.၃%
08/12/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
၄၃.၀၀ US$
+၄၅.၇%
08/13/2026
Boris Peaker
JonesTrading
Buy
Maintained
၄၅.၀၀ US$
+၅၂.၅%
08/12/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
၃၁.၇၄ US$
+၇.၆%
06/22/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
၄၅.၀၀ US$
+၅၂.၅%
05/29/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
၄၄.၀၀ US$
+၄၉.၁%
05/12/2026
Soumit Roy
JonesTrading
Buy
Maintained
၄၅.၀၀ US$
+၅၂.၅%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၃.၂၂ ကုဋေ
၃.၂၂ ကုဋေ
၃.၇၆ ကုဋေ
၄.၂၃ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၆.၁၅ သန်း
၆.၆၅ သန်း
၈.၄၉ သန်း
၁.၀၄ ကုဋေ
Operating expense
၃.၈၃ ကုဋေ
၃.၈၈ ကုဋေ
၄.၆၁ ကုဋေ
၅.၂၇ ကုဋေ
Total operating expenses
၃.၈၃ ကုဋေ
၃.၈၈ ကုဋေ
၄.၆၁ ကုဋေ
၅.၂၇ ကုဋေ
Operating income
-၃.၈၃ ကုဋေ
-၃.၈၈ ကုဋေ
-၄.၆၁ ကုဋေ
-၅.၂၇ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၃.၄၈ ကုဋေ
-၃.၆၀ ကုဋေ
-၄.၃၃ ကုဋေ
-၄.၉၉ ကုဋေ
EBT excluding unusual items
-၃.၅၀ ကုဋေ
-၃.၅၅ ကုဋေ
-၄.၃၃ ကုဋေ
-၄.၉၉ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၃.၄၈ ကုဋေ
-၃.၆၀ ကုဋေ
-၄.၃၃ ကုဋေ
-၄.၉၉ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၈၃
-၀.၇၈
-၀.၉၆
-၁.၀၅
Interest and investment income
၃.၃၄ သန်း
၃.၂၈ သန်း
၂.၇၉ သန်း
၂.၈၀ သန်း
Interest expense
-
-
-
-
Net interest expenses
၃.၃၄ သန်း
၃.၂၈ သန်း
၂.၇၉ သန်း
၂.၈၀ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ